News Details
NCCN Releases Growth Factors and Lung, Kidney, Testicular, Gastric and Esophageal Cancers Chapters of the NCCN Drugs & Biologics Compendium™
JENKINTOWN, Pa., September 13, 2005 — The National Comprehensive Cancer Network (NCCN) announces important new additions to the NCCN Drugs & Biologics Compendium™, an authoritative source of evaluative information on the appropriate use of drugs and biologics in cancer care. NCCN has added the following titles to the list of available Compendium chapters:
- Kidney Cancer
- Testicular Cancer
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Cancer- and Treatment-Related Anemia
- Myeloid Growth Factors in Cancer Treatment
- Gastric Cancer
- Esophageal Cancer
“A variety of constituencies in the health care community look to NCCN for evaluative information to aid their decision-making. NCCN again is responding to these needs by providing evaluative data in an easy-to-use format,” said William T. McGivney, Ph.D., CEO of NCCN. “One target audience for the NCCN Drugs & Biologics Compendium™ comprises decision-makers at insurance/managed care companies, PBMs, etc. who seek authoritative and definitive information to establish coverage policies. In cancer care, the issue of the appropriateness of use beyond FDA-approved labeling is critical and is addressed extensively by the Compendium.”
The NCCN Drugs & Biologics Compendium™ delineates the appropriate uses of drugs and biologics in the care of patients with cancer. The Compendium’s identified uses are derived directly from the NCCN Clinical Practice Guidelines in Oncology, the recognized standard for clinical policy in oncology. As with the guidelines, the Compendium will span the continuum of cancer care from early stage to advanced stage disease, and from supportive care to palliative care. The Compendium is made available free of charge in user-friendly electronic and paper formats.
The Compendium lists disease indications and specific recommendations for use as described in the NCCN Guidelines. The end-user will also be provided the recommendation category that defines the level of evidence and degree of consensus that support the recommendation.
For the most recent versions of Compendium chapters and for more information about the NCCN Drugs & Biologics Compendium™ and other NCCN programs, please contact NCCN at 215-690-0255 or at www.nccn.org.